Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link FDA's Overreach on Compounded Peptides The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide The FDA just put peptides like BPC 157, TB 500, and KPV on the clock. , As a compounding pharmacist, this is literally my world and most people dont understand the regulatory nuance behind what